Licensing

With over 29 years of experience and operating across all key life science sectors, PharmaVentures offers deep sector expertise to support your M&A and funding transactions.

We support our clients with strategic advice and full end-to-end process management capabilities to achieve best o...

Operating across all key life science sectors, PharmaVentures offers deep sector expertise to help you derive optimal value from your funding transactions.

We support our clients with strategic advice and full end-to-end process management capabilities to achieve the best outcome from their stra...

Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With ample capital available in the sector, it comes as no surprise that PwC forecasts M&A deals will reach $400 billion this year.  

What will this webinar address? Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape. Partnerships and mergers are a key tool for adding value to pharmaceutical companies; helping to navigate technological limitations, address portfolio challenges and chase innovation. This webinar, delivered in partnership with PharmaVentures, will examine the trends and developments driving deal-making in the current market. When you attend this webinar, you will discover: The key acquisition drivers for Pharma Manufacturers and CDMOs (tech, therapy areas, patent losses, portfolio challenges) What does the future look like? Prior to the COVID-19 pandemic, M&A activity in pharmaceuticals was soaring with $414 billion worth of deals in 2019 . What will the short to mid-term impact be on deal-making? How is ‘reshoring’ transforming the pharma manufacturing map and impacting Governments?